Effects of repeated periods of high-intensity interval training on myocardial function in patients with metabolic syndrome: A 16-month follow-up.

J CardiolMay 4, 2026 (epub)
Clinical ResearchCardiologyEndocrinology

Juan F Ortega, Eva García-Camacho, Alejandro Gadella-Fernández et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial investigated the effects of two periods of high-intensity interval training (HIIT) on myocardial function in 88 middle-aged patients with metabolic syndrome over 16 months. The study found that HIIT significantly improved left ventricle global longitudinal strain (LV-GLS) and early diastolic function compared to standard medical treatment alone, with a notable group*time interaction (p=0.002).

Key findings

  • LV-GLS improved progressively after two HIIT periods compared to control (p=0.002).
  • LV-early rapid filling parameters also showed significant improvement in the HIIT group (p=0.028).
  • Maximal oxygen consumption (VO2max) increased only in the HIIT group (p=0.002).

Why it matters

Improving myocardial function in patients with metabolic syndrome is crucial, as these individuals are at increased risk for cardiovascular disease. This study suggests that incorporating HIIT into treatment regimens may enhance cardiac health in this population.

Source

PubMed · PMID 42086168

Published in J Cardiol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.